Mir-375 enhances ruthenium-derived compound Rawq01 induced cell death in human ovarian cancer.

UNLABELLED: Ovarian cancer is one of the most common gynecological malignancies. Limited efficacy of cytotoxic chemotherapy is a key obstacle in the treatment of advanced ovarian cancer. This study aimed to investigate whether Mir-375 enhances Rawq01 (a ruthenium derived compound) induced cell death in ovarian cancer. METHODS: Three human ovarian cancer cell lines were selected, and independently treated with Rawq01+mir-375 and Rawq01+control. MTT assay and flow cytometry were performed to detect the growth of ovarian cancer cells. Western blot was carried out to determine the expression of apoptotic associated proteins. In addition, ovarian cancer xenografts were established to explore whether mir-375 increased the in vivo chemosensitivity of ovarian cancer cells to RAWQ01. RESULTS: Over-expression of mir-375 sensitized the ovarian cancer cells to RAWQ01. Mir-375 enhanced the in vitro sensitivity of ovarian cancer cells to RAWQ01 by inducing apoptosis. Mir-375 also increased the in vivo chemosensitivity of ovarian cancer cells to RAWQ01. CONCLUSION: Mir-375 can enhance Rawq01 induced cell death in human ovarian cancer both in vitro and in vivo.